| Prev Close: | 35.92 |
|---|
| Open: | N/A |
|---|
| Bid: | 35.73 x 200 |
|---|
| Ask: | 36.14 x 1000 |
|---|
| 1y Target Est: | 30.05 |
|---|
| Beta: | 0.6 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 28.62 - 37.78 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 1,531,550 |
|---|
| Market Cap: | 5.94B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.44 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- U.S. court ruling favors Cubist in patent case versus HospiraReuters(Mon, May 20)
- U.S. court ruling favors Cubist in patent case vs Hospiraat Reuters(Mon, May 20)
- Interesting HSP Put And Call For Julyat TheStreet(Mon, May 20)
- Cubist Pharmaceuticals shares leap late after ruling on patent casesat MarketWatch(Mon, May 20)
- Cubist move higher attributed to patent construction in suit against Hospiratheflyonthewall.com(Mon, May 20)
- South Korea's Celltrion sale seen slow-going as sceptics emergeat Reuters(Tue, May 14)
- Hospira's former chief scientific officer returnsAP(Tue, May 14)
- Markman Hearing A Likely Clearing Event For Cubist - Decision Any Dayat Seeking Alpha(Tue, May 14)
- Synta Is a Run-Up Trade Into ASCO Lung Cancer Dataat TheStreet(Tue, May 14)
- Hospira Reappoints Dr. Sumant Ramachandra Chief Scientific OfficerPR Newswire(Tue, May 14)
- HOSPIRA INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, May 14)
- Hospira Inc. (HSP): Today's Featured Health Care Laggardat TheStreet(Mon, May 13)
- Stocks to Watch: Theravance, Endo Health, Perion Networkat The Wall Street Journal(Mon, May 13)
- [$$] Where European Investors Look for Valueat Barrons.com(Sat, May 11)
- Hospira Becomes #24 Most Shorted S&P 500 Component, Replacing Leggett & Plattat TheStreet(Fri, May 10)
Key Statistics
| Forward P/E (1 yr): | 17.35 |
|---|
| P/S (ttm): | 1.48 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.03 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.51 |
|---|
| Mean Recommendation*: | 3.4 |
|---|
| PEG Ratio (5 yr expected): | 2.38 |
|---|
Business Summary
Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and markets products worldwide. The company offers specialty injectable pharmaceuticals, which include approximately 200 injectable generic drug...
View More 
0.34%